Welcome to our dedicated page for 60 DEGREES PHARMACEUTICALS SEC filings (Ticker: SXTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. is registering up to 1,769,593 shares of common stock for resale by existing selling stockholders. These include outstanding shares and shares issuable from pre-funded warrants, Series A and B common warrants, and placement agent warrants issued in a July 30, 2026 private placement. The company is not selling any shares and will receive no proceeds from stockholder resales, only any cash paid upon warrant exercise.
The company is a specialty pharmaceutical business focused on infectious diseases, led by its FDA-approved malaria prophylaxis Arakoda (tafenoquine). It is pursuing additional indications such as babesiosis, chronic babesiosis, and veterinary babesiosis through multiple clinical trials, while also advancing early programs in viral diseases via Celgosivir and Australian Chestnut Extract. Prior financing has included at-the-market offerings and a 1:4 reverse stock split that restored compliance with Nasdaq listing rules.
60 Degrees Pharmaceuticals, Inc. reported that for the six months ended June 30, 2026, net revenue was $133,175, down from $440,831 a year earlier as prior-period research revenue did not recur, while net product revenue increased. Operating expenses rose to $4,499,238, leading to a net loss attributable to the company of $4,353,740 and a net loss attributable to common stockholders of $4,604,865. Net cash used in operating activities was $4,973,280.
Cash and cash equivalents were $1,022,606 and total assets $4,282,694 at June 30, 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern for one year from issuance, even after raising approximately $3.37 million through at-the-market offerings in early 2026 and disclosing an additional ~$0.7 million in net proceeds from a July 2026 PIPE offering. The company also carries a Level 3 derivative liability of $384,973 tied to a potential $10 million milestone payment to Knight Therapeutics and has significant customer concentration, with a small number of distributors accounting for most receivables and product revenues.
60 Degrees Pharmaceuticals, Inc. held its virtual 2026 annual stockholders meeting on August 5, 2026. As of the July 2, 2026 record date, 2,659,288 shares of common stock were outstanding. Holders of 1,107,592 shares, about 41.6% of the voting shares, were represented in person or by proxy, establishing a quorum pursuant to the Delaware General Corporation Law and the company’s amended and restated bylaws.
Stockholders cast more votes “for” than “withheld” for each of the five director nominees, including Geoffrey Dow (147,223 for; 25,031 withheld) and Eric Francois (141,202 for; 31,052 withheld), with 935,338 broker non-votes on each election. For each additional proposal on the agenda, the required affirmative vote of a majority of shares represented at the meeting was achieved, and each proposal was approved, with reported “for” votes ranging from 92,303 to 997,089.
60 Degrees Pharmaceuticals, Inc. received a Schedule 13G from Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton reporting a beneficial ownership position in its common stock.
Each reporting person has sole voting and dispositive power over 191,571 shares, representing 5.45% of the common stock. Their holdings consist of 191,571 shares of common stock and 191,571 Series A Warrants plus 191,571 Series B Warrants. Due to conversion limitations in the warrants, their beneficial ownership is limited to an aggregate of 191,571 shares. The warrants include a provision that restricts conversion if it would cause the holder to beneficially own more than 4.99% of the company.
60 Degrees Pharmaceuticals entered into securities purchase agreements with institutional investors on July 30, 2026 for a private placement priced at-the-market under Nasdaq rules. The company is issuing 191,571 shares of common stock at $1.74 per share and pre-funded warrants for 383,142 shares at $1.739, together with Series A and Series B common stock warrants.
The transaction covers a total of 574,713 common shares (or pre-funded warrants) plus Series A and short-term Series B warrants to purchase up to 574,713 shares each, all with an exercise price of $1.49 per share. Gross proceeds are approximately $1.0 million, before fees and expenses, with intended use for working capital, general operations and the company’s research and development program.
Pre-funded warrants are exercisable immediately at $0.001 per share and remain outstanding until fully exercised. The Series A warrants expire five years after the effective date of a resale registration statement and the Series B warrants after 24 months, and both are subject to a Beneficial Ownership Limitation generally capping holders at 4.99% or, at their election, 9.99% of outstanding common stock. H.C. Wainwright & Co. receives a 7.5% cash fee, a 1.0% management fee, expense reimbursements and warrants to purchase 43,103 shares at $2.175 per share. The unregistered securities rely on Section 4(a)(2) and Rule 506 of Regulation D, and the company has agreed to file resale registration statements using best efforts within 45 days of July 30, 2026, or 75 days if subject to full SEC review.
Knight Therapeutics Inc. reports initial insider ownership in 60 Degrees Pharmaceuticals, Inc. (SXTP) as a ten percent owner. It holds 658,629 shares of common stock, $0.0001 par value per share, directly as of July 22, 2026, with no buy or sell transaction specified.
Knight Therapeutics Inc. filed a Schedule 13G reporting a passive ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock. As of July 22, 2026, Knight beneficially owns 658,629 shares of common stock, representing 19.85% of the class. This percentage is based on 2,659,288 shares outstanding as of May 15, 2026. Knight has sole voting power and sole dispositive power over all 658,629 shares, with no shared voting or dispositive power reported.
60 Degrees Pharmaceuticals, Inc. furnished an updated investor presentation describing its strategy to develop and commercialize products for vector-borne diseases. The company’s lead product is ARAKODA (tafenoquine), an FDA-approved malaria prophylaxis since 2018 targeting a stated $50–70M U.S. malaria prevention market.
The presentation outlines plans to expand tafenoquine into babesiosis, including FDA orphan-drug status granted in 2024 and multiple clinical programs: a randomized hospital study in acute babesiosis with an interim analysis planned after at least 24 patients by late 2026, an expanded-access study in relapsing immunosuppressed patients, and a Phase II open-label study in chronic babesiosis.
Management highlights intellectual property with four Orange Book-listed U.S. patents for tafenoquine expiring in December 2035, recent equity financing (a $5M public offering and about $4M raised via an at-the-market program), and 2.66 million common shares outstanding as of March 31, 2026. The risk discussion includes substantial doubt about the company’s ability to continue as a going concern, dependence on clinical success, eligibility for research incentives, and reliance on third-party manufacturing.
60 Degrees Pharmaceuticals outlined its statistical analysis plan for an interim look at its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis. An interim analysis is planned for the earlier of October 30, 2026 or after 24 of 33 planned patients have been randomized and followed for at least 50 days.
The plan uses conditional power analyses for time to sustained clinical resolution and time to molecular cure, with potential early reporting or sample size increase up to 66 patients. As of this notice, 23 patients had been enrolled. If results support an sNDA, the company aims to pursue a Commissioner’s National Priority Review Voucher before the end of the first quarter of 2028.
60 Degrees Pharmaceuticals is asking stockholders to approve several major governance items at its 2026 virtual annual meeting on August 5, 2026. Holders of 2,659,288 shares outstanding as of July 2, 2026 can vote by telephone or mail.
Stockholders will vote on electing five directors, including proposed new director and audit chair Eric Francois, expanding the 2022 Equity Incentive Plan by 800,000 shares to a total reserve of 962,889 shares, and authorizing a reverse stock split at a ratio between 1:5 and 1:10 at the Board’s discretion. Other proposals include ratifying RBSM LLP as auditor, approving a management success fee tied to a change of control or strategic transaction, and allowing adjournment to solicit additional proxies.